Effective therapy for acute antibody-mediated rejection with mild chronic changes: case report and review of the literature.
作者： Osama Gheith , Torki Al-Otaibi , Narayanan Nampoory , Medhat Halim , Prasad Nair
关键词:
摘要: Abstract To reduce the long-term toxicities of immunosuppressant drugs, corticosteroid-sparing and calcineurin-inhibitor-sparing immunosuppression protocols have become increasingly popular in managing kidney transplant recipients. The most vexing clinical condition caused by antibodies organ transplants is antibody-mediated rejection. Limitations current rejection therapies include (1) reversal tends to be gradual rather than prompt, (2) expense, (3) rates below 80%, (4) common appearance chronic after treatment, (5) persistence donor specific therapy. Because these limitations may due a lack effects on mature plasma cells, bortezomib cells represent quantum advance antihumoral Our experiences first use as an agent renal allograft recipients Kuwait. We present 2 cases with resistant-acute standard that were managed successfully bortezomib.
sci-hub.st 参考文章(15)
Diego Cantarovich, Fabio Vistoli, Minimization protocols in pancreas transplantation. Transplant International. ,vol. 22, pp. 61- 68 ,(2009) , 10.1111/J.1432-2277.2008.00738.X
I. Helal, L. Chan, Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation. Congress of the Middle East Society for Organ Transplantation (MESOT). ,vol. 43, pp. 472- 477 ,(2011) , 10.1016/J.TRANSPROCEED.2011.01.054
Matilde Bustos, Soheyla Saadi, Jeffrey L. Platt, Platelet-mediated activation of endothelial cells: implications for the pathogenesis of transplant rejection. Transplantation. ,vol. 72, pp. 509- 515 ,(2001) , 10.1097/00007890-200108150-00025
Matthew J. Everly, Jason J. Everly, Brian Susskind, Paul Brailey, Lois J. Arend, Rita R. Alloway, Prabir Roy-Chaudhury, Amit Govil, Gautham Mogilishetty, Adele H. Rike, Michael Cardi, George Wadih, Amit Tevar, E Steve Woodle, Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. ,vol. 86, pp. 1754- 1761 ,(2008) , 10.1097/TP.0B013E318190AF83
C. Ponticelli, M.P. Scolari, Calcineurin Inhibitors in Renal Transplantation Still Needed but in Reduced Doses: A Review Congress of the Italian Society for Safety and Quality in Transplantation (SISQT). ,vol. 42, pp. 2205- 2208 ,(2010) , 10.1016/J.TRANSPROCEED.2010.05.036
Alexander T. Chang, Jeffrey L. Platt, The role of antibodies in transplantation Transplantation Reviews. ,vol. 23, pp. 191- 198 ,(2009) , 10.1016/J.TRRE.2009.06.002
Steven K. Takemoto, Adriana Zeevi, Sandy Feng, Robert B. Colvin, Stanley Jordan, Jon Kobashigawa, Jerzy Kupiec-Weglinski, Arthur Matas, Robert A. Montgomery, Peter Nickerson, Jeffrey L. Platt, Hamid Rabb, Richard Thistlethwaite, Dolly Tyan, Francis L. Delmonico, National conference to assess antibody-mediated rejection in solid organ transplantation. American Journal of Transplantation. ,vol. 4, pp. 1033- 1041 ,(2004) , 10.1111/J.1600-6143.2004.00500.X
Shamila Mauiyyedi, Robert B. Colvin, Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Current Opinion in Nephrology and Hypertension. ,vol. 11, pp. 609- 618 ,(2002) , 10.1097/00041552-200211000-00007
Stuart M. Flechner, Richard Fatica, Medhat Askar, Brian R. Stephany, Emilio Poggio, Anna Koo, Stacey Banning, Andres Chiesa-Vottero, Titte Srinivas, The Role of Proteasome Inhibition With Bortezomib in the Treatment of Antibody-Mediated Rejection After Kidney-Only or Kidney-Combined Organ Transplantation Transplantation. ,vol. 90, pp. 1486- 1492 ,(2010) , 10.1097/TP.0B013E3181FDD9B0
Hargovind L. Trivedi, Paul I. Terasaki, Aziz Feroz, Matthew J. Everly, Aruna V. Vanikar, Vangipurapu Shankar, Varsha B. Trivedi, Hugo Kaneku, Adam K. Idica, Pranjal R. Modi, Sajani I. Khemchandani, Shruti D. Dave, Abrogation of Anti-HLA Antibodies via Proteasome Inhibition Transplantation. ,vol. 87, pp. 1555- 1561 ,(2009) , 10.1097/TP.0B013E3181A4B91B